Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 30;143(13):1338-1340.
doi: 10.1161/CIRCULATIONAHA.120.053311. Epub 2021 Feb 15.

Multiple Biomarker Approach to Risk Stratification in COVID-19

Nathaniel R Smilowitz  1   2 , Vuthy Nguy  3 , Yindalon Aphinyanaphongs  3 , Jonathan D Newman  1 , Yuhe Xia  1 , Harmony R Reynolds  1 , Judith S Hochman  1 , Glenn I Fishman  1 , Jeffrey S Berger  1   4
Affiliations

Multiple Biomarker Approach to Risk Stratification in COVID-19

Nathaniel R Smilowitz et al. Circulation. .
No abstract available

Keywords: C-reactive protein; COVID-19; biomarkers; fibrin fragment D; inflammation; troponin.

PubMed Disclaimer

Figures

Figure.
Figure.
The frequency of elevated biomarkers reflecting myocardial injury, coagulation, and inflammation in COVID-19 and associations with in-hospital outcomes. A, Venn diagram illustrating overlap of elevated biomarkers at the time of initial hospital presentation in patients with COVID-19 and ≥1 elevated biomarker (n=2699). One hundred ninety-six patients had no elevated biomarkers. The proportion of patients with in-hospital mortality (B) and critical illness (C) are shown stratified by the number of elevated biomarkers measured at hospital presentation with COVID-19. Odds ratios (versus 0 biomarkers elevated) shown in B and C are adjusted for age, sex, race, body mass index, tobacco use, hypertension, hyperlipidemia, diabetes, chronic kidney disease, prior myocardial infarction, prior heart failure, atrial fibrillation, temperature at presentation, pulse oximetry at presentation, and outpatient prescriptions for antiplatelets, statin, and β-blockers. aOR indicates adjusted odds ratio; and CRP, C-reactive protein.
See this image and copyright information in PMC

References

    1. Berger JS, Kunichoff D, Adhikari S, Ahuja T, Amoroso N, Aphinyanaphongs Y, Cao M, Goldenberg R, Hindenburg A, Horowitz J, et al. . Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. Arterioscler Thromb Vasc Biol. 2020;40:2539–2547. doi: 10.1161/ATVBAHA.120.314872 - PMC - PubMed
    1. Smilowitz NR, Jethani N, Chen J, Aphinyanaphongs Y, Zhang R, Dogra S, Alviar CL, Keller N, Razzouk L, Quinones-Camacho A, et al. . Myocardial injury in adults hospitalized with COVID-19. Circulation. 2020;142:2393–2395. doi: 10.1161/CIRCULATIONAHA.120.050434 - PMC - PubMed
    1. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. C-reactive protein and clinical outcomes in patients with COVID-19 [published January 15, 2021]. Eur Heart J. doi: 10.1093/eurheartj/ehaa1103. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj... - DOI - PMC - PubMed
    1. Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, Boersma WG. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138:1108–1115. doi: 10.1378/chest.09-2927 - PubMed
    1. Komiya K, Ishii H, Teramoto S, Takahashi O, Eshima N, Yamaguchi O, Ebi N, Murakami J, Yamamoto H, Kadota J. Diagnostic utility of C-reactive protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study. Respir Res. 2011;12:83. doi: 10.1186/1465-9921-12-83 - PMC - PubMed

Publication types